18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 20
Summary
- Conditions
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR or PET/CT scannerMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 5 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02348749
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Neeta Pandit-Taskar, MD Memorial Sloan Kettering Cancer Center
Get Well Soon